Change in the frequency of HRT use from 2000 to 2005 and reasons to discontinue: Follow-up of a normal cohort in Finland

Acta Obstetricia et Gynecologica Scandinavica

Volumn 90, Issue 4, 2011, Pages 351-357

  Jalava Broman, Jaana ^a,b   Mãkinen, Juha ^c   Ojanlatva, Ansa ^a,d   Jokinen, Kirsi ^e   Sillanmãki, Lauri ^f   Rautava, Pãivi ^a,c  

^a UNIVERSITY OF TURKU   (Finland)

^b Turku Municipal Health Care and Social Services   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d TURKU CITY HOSPITAL   (Finland)

^e University of Turku ^*  (Finland)

^f UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Climacteric; hormone therapy; hot flushes; menopause; middle aged women

Indexed keywords

ESTROGEN; SEX HORMONE;

ADULT; ANXIETY; ARTICLE; BLEEDING; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; CLIMACTERIUM; COHORT ANALYSIS; DEPRESSION; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECZEMA; ESTROGEN THERAPY; FEMALE; FINLAND; FOLLOW UP; HUMAN; HYPERTENSION; LIBIDO; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MOOD CHANGE; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SIDE EFFECT; TREATMENT WITHDRAWAL; WEIGHT GAIN;

COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FINLAND; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; LOGISTIC MODELS; MENOPAUSE; MIDDLE AGED; QUESTIONNAIRES; SOCIOECONOMIC FACTORS;

EID: 79952971234     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/j.1600-0412.2011.01069.x     Document Type: Article

References (33)

1. Hersh A, Stefanick M, Stafford R,. National use of postmenopausal hormone therapy. JAMA. 2004; 291: 47-53.
2. SÃgaard A, Tollan A, Berntsen G, FÃnnebà V, Magnus J,. Hormone replacement therapy: knowledge, attitudes, self-reported use-and sales figures in Nordic women. Maturitas. 2000; 35: 201-14. (Pubitemid 30628816)
3. Jalava-Broman J, Mäkinen J, Ojanlatva A, Jokinen K, Sillanmäki L, Rautava P,. Treatment of climacteric symptoms in Finland prior to the controversial reports on hormone therapy. Acta Obstet Gynecol Scand. 2008; 87: 682-6. (Pubitemid 351890358)
4. Grodstein F, Stampfer M, Colditz G, Willet W, Manson J, Joffe M, et al,. Postmenopausal hormone therapy and mortality. N Eng J Med. 1997; 336: 1769-75.
5. Mikkola T, Clarkson T,. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002; 53: 605-19. (Pubitemid 34175253)
6. Schneider D, Barrett-Connor E, Morton D,. Timing of postmenopausal estrogen for optimal bone mineral density. JAMA. 1997; 277: 543-7. (Pubitemid 27083983)
7. Jacobs D, Tang M, Stern Y, Sano M, Marder K, Bell K, et al,. Cognitive function in non-demented older women who took estrogen after menopause. Neurology. 1998; 50: 368-73. (Pubitemid 28119772)
8. Nanda K, Bastian L, Hasselblad V, Simel D,. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol. 1999; 93: 880-8. (Pubitemid 29197937)
9. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al,. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998; 280: 605-13. (Pubitemid 28502636)
10. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al,. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288: 49-57. (Pubitemid 34705518)
11. Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Hutchinson F, et al,. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002; 288: 321-33.
12. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362: 419-27.
13. Majumdar S, Almasi E, Stafford R,. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA. 2004; 292: 1983-8. (Pubitemid 39411207)
14. Hoffman M, Hammar M, Kjellgren K, Lindh-Ãstrand L, Brynhildsen J,. Changes in women's attitudes towards and use of the hormone therapy after HERS and WHI. Maturitas. 2005; 52: 11-7. (Pubitemid 41242737)
15. Salmi T, Paldán M, Virta L, Klaukka T,. Vaihdevuosihormonien käyttö on vähentynyt edelleen [Use of menopausal hormone drugs further declined. Suom. Lääkärilehti. 2006; 48: 5064-6.
16. Korkeila K, Suominen S, Ahvenainen J, Ojanlatva A, Rautava P, Helenius H, et al,. Non-response and related factors in a nationwide health survey. Eur J Epidemiol. 2001; 17: 991-9.
17. Stadberg E, Mattsson L-Ã, Milsom I,. Factors associated with climacteric symptoms and the use of hormone replacement therapy. Acta Obstet Gynecol Scand. 2000; 79: 282-92.
18. Kupperman HS, Blatt MH, Wiesbader H, Filler W,. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. Endocrinology. 1953; 13: 688-703.
19. Oldenhave A, Jaszmann L, Haspels A, Everaerd W,. Impact of climacteric on well-being. Am J Obstet Gynecol. 1993; 168: 772-80.
20. Mishra G, Kok H, Ecob R, Cooper R, Hardy R, Kuh D,. Cessation of hormone replacement therapy after reports of adverse findings from randomized controlled trials: evidence from a British birth cohort. Am J Public Health. 2006; 96: 1219-25. (Pubitemid 43967847)
21. Waaseth M, Bakken K, Lund E,. Patterns of hormone therapy use in the Norwegian Women and Cancer study (NOWAC) 1996-2005. Maturitas. 2009; 63: 220-6.
22. Hemminki E, Kyyrönen P, Pukkala E,. Postmenopausal hormone drugs and breast and colon cancer: Nordic countries 1995-2000. Maturitas. 2008; 61: 299-304.
23. Salmi T, Paldán M, Klaukka T,. Vaihdevuosihormonien käyttö on vähentynyt maan kaikissa osissa [Use of menopausal hormone drugs declined in all parts of the country. Suom. Lääkä rilehti. 2004; 59: 1042-5.
24. Vihtamäki T, Savilahti R, Tuimala R,. Why do postmenopausal women discontinue hormone replacement therapy? Maturitas. 1999; 33: 99-105. (Pubitemid 29509929)
25. Tiihonen M, Heikkinen A-M, Ahonen R,. Do Finnish women using hormone replacement therapy need more information about risks. Pharm World Sci. 2007; 29: 635-40. (Pubitemid 47594168)
26. Ã̃ren A,. Motives for initiation, temporary discontinuation, and permanent discontinuation of hormone replacement therapy use among Norwegian women. Maturitas. 2009; 64: 33-7.
27. Lindh-Ãstrand L, Brynhildsen J, Hoffmann M, Liffner S, Hammar M,. Attitudes towards the menopause and hormone therapy over the turn of the century. Maturitas. 2007; 56: 12-20. (Pubitemid 44894785)
28. Moen M, Nilsen S-T, Iversen O-E,. A significant change in Norwegian gynecologist's attitude to hormone therapy is observed after the results of the Women's Health Initiative Study. Acta Obstet Gynecol Scand. 2005; 84: 92-3. (Pubitemid 40179495)
29. Hemminki E,. Opposition to unpopular research results: Finnish professional reactions to the WHI findings. Health Policy. 2004; 69: 283-291. (Pubitemid 38970089)
30. Topo P, Koster A, Holte A, Collons A, Langgren B-M, Hemminki E, et al,. Trends in the use of climacteric and postclimacteric hormones in Nordic countries. Maturitas. 1995; 22: 89-95.
31. Col N, Guthrie J, Politi M, Dennerstein L,. Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause. 2009; 16: 453-7.
32. Barbaglia G, Macia F, Comas M, Sala M, Vernet M, Casamitjana M, et al,. Trends in hormone therapy use before and after publication of the Women's Health Initiative trial:10 years of follow-up. Menopause. 2009; 16: 1061-4.
33. Thunell L, Stadberg E, Milsom I, Mattsson L-Ã,. Changes in attitudes, knowledge and hormone replacement therapy use: a comparative study in two random samples with 6-year interval. Acta Obstet Gynecol Scand. 2005; 84: 395-401. (Pubitemid 40478192)